GlassScriptPhysician profile
Roger I Ceilley
NPI 1992758122
$82,119.90
in general payments reported to CMS, 2019-2025
35 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $14K · 2021: $9,991 · 2022: $4,008 · 2023: $6,135 · 2024: $3,399 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,265 · Consulting Fee: $8,200 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,840.40 |
| Food and Beverage | $8,264.80 |
| Consulting Fee | $8,200.00 |
| Education | $285.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $11,518.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11,457.29 | 2019-2025 | Libtayo, Dupixent |
| Biofrontera INC. | $9,173.12 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $8,727.79 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Vyne Pharmaceuticals INC. | $8,713.96 | 2020-2021 | |
| Almirall LLC | $7,755.34 | 2019-2023 | Klisyri, Seysara |
| Leo Pharma INC. | $6,374.79 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $3,571.33 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $3,095.05 | 2020-2025 | Bimzelx, Cimzia |
| Stemline Therapeutics INC. | $2,071.20 | 2021-2022 | |
| Pfizer INC. | $1,973.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,380.69 | 2019-2025 | |
| Abbvie INC. | $1,312.37 | 2019-2025 | Skyrizi, Rinvoq |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,024.29 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Janssen Biotech, INC. | $778.73 | 2019-2025 | Tremfya |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $691.26 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Dermavant Sciences, INC. | $449.86 | 2023 | Vtama |
| Lilly USA, LLC | $335.52 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $249.24 | 2019-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $238.18 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.53 | 2023-2025 | Spevigo, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $185.82 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $181.41 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $176.14 | 2023 | |
| Verrica Pharmaceuticals INC. | $95.37 | 2023-2025 | Ycanth |
| Kerecis Limited | $92.26 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Genentech USA, INC. | $66.42 | 2019-2024 | Erivedge |
| Janssen Scientific Affairs, LLC | $52.42 | 2025 | Tremfya |
| Organon LLC | $50.82 | 2025 | Hadlima, Vtama |
| Prugen, INC. Pharmaceuticals | $36.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Aclaris Therapeutics, INC. | $24.34 | 2019 | |
| Botanix Sb INC | $13.57 | 2025 | Sofdra |
| Celgene Corporation | $13.38 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Ceilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.